icon-    folder.gif   Conference Reports for NATAP  
  Fatty Liver Disease

Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive
Protein Biomarkers for Diagnosis and Monitoring of NASH

  Reported by Jules Levin
EASL 2018 April 11-15 Paris france
Michelle Lai,1 Towia Libermann,1 Michael Charlton,2 Anna Mae Diehl,3 Long Ngo,1 Simon Dillon,1 Eric J. Lawitz,4 Naga Chalasani,5 Bilal Hameed,6 Stephen Caldwell,7 Mary Rinella,8 Tuan Nguyen,9 Andrew N.Billin,9 C. Stephen Djedjos,9 G. Mani Subramanian,9 Robert P. Myers,9 Zachary Goodman,10 Rohit Loomba,11 Nezam H. Afdhal1 1Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; 2University of Chicago, Illinois, USA; 3Duke Clinical Research Institute, Durham, North Carolina, USA; 4Texas Liver Institute and UT Health San Antonio, Texas, USA; 5Indiana University School of Medicine, Indianapolis, Indiana, USA; 6University of California San Francisco, California, USA; 7University of Virginia, Charlottesville, Virginia, USA; 8Northwestern Medicine, Chicago, Illinois, USA; 9Gilead Sciences, Inc., Foster City, California, USA; 10Inova Fairfax Hospital, Falls Church, Virginia, USA; 11UC San Diego, La Jolla, California, USA








1. Loomba R, et al. Hepatology 2017;67:549-59; 2. Gold L, et al. PLoS One 2010;5:e15004.